Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
Ahmed Ibrahim, Medical Student at Alexandria University, shared a post on LinkedIn about a recent article that he and his colleagues co-authored:
“For patients with ischemic stroke and comorbid Atrial Fibrillation (AF) and Atherosclerotic Cardiovascular Disease (ASCVD), does adding an antiplatelet to an anticoagulant do more harm than good in secondary stroke prevention?
Key Findings from our Network Meta-Analysis (should be interpreted with caution and contextualized within the study’s limitations):
The Power of One: OAC monotherapy emerged as the most favorable strategy for secondary prevention. It provides a balanced profile, offering strong protection against recurrent strokes with potential lower risk of major bleeding compared to combination therapy.
Less is More: Adding antiplatelet therapy (APT) to an anticoagulant did not provide additional clinical benefit. It may increase the risk of major bleeding without significantly reducing the risk of further ischemic events or death.
APT Alone: While APT monotherapy had the lowest bleeding risk, it was associated with a concerning trend toward increased all-cause mortality and was the least effective at preventing recurrent ischemic strokes.
Take-Home Message:
- In secondary stroke prevention for patients with AF and ASCVD, OAC monotherapy appears to offer a favorable balance between efficacy and safety.
- While combination therapy may be considered in select cases with compelling indications, routine use of antiplatelet therapy alongside anticoagulation should be approached with caution due to potential increased bleeding risk without clear added benefit.
Grateful to my colleagues Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio villari.
Heartfelt thanks to our seniors, Prof. Giuseppe Andò and Dr. Pierre F. Sabouret, for their invaluable support and guidance.”
Title: Optimal antithrombotic therapy for post-ischemic stroke patients with atrial fibrillation and atherosclerotic cardiovascular disease: A frequentist network meta-analysis
Authors: Ahmed Ibrahim, Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio Villari, Giuseppe Andò, Pierre Sabouret
Read Full Article on Journal of the Neurological Sciences.
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026